基于荧光效应的小分子抗癌药物释放体系研究进展

doi:10.11944/j.issn.1000-0518.2019.07.190040

摘要/Abstract

摘要：

近年来,随着癌症发病率的不断升高,癌症治疗技术的更新和发展显得尤为重要,特别是化学疗法(Chemotherapy)的提出促进了荧光小分子抗癌药物释放体系的研究。将具有荧光效应的有机小分子与抗癌药物结合在一起,使得药物释放体系表现出低毒性、优异的癌细胞靶向性和方便药物跟踪监测等特点。因此,设计不同性能的前药可以研究抗癌药物释放的动力学过程,为实现癌症的精准治疗提供有力的工具。本文主要介绍了基于喜树碱、SN-38和阿霉素等前药的研究进展,并对其发展前景作了展望。

关键词: 药物释放, 化学疗法, 癌症治疗, 喜树碱, 荧光小分子

Abstract:

In recent years, with the rising incidence of cancer, the renewal and development of cancer therapy technology is particularly important. Especially, the introduction of chemotherapy has promoted the research for the release system of fluorescence small molecule anticancer drugs. An anticancer drug release system combines organic fluorescent molecules with anticancer drugs based on fluorescent effect, which has the characteristics of low toxicity, excellent targeting to cancer cells and convenience to track and monitor. Therefore, design of prodrugs with different properties can be used to study the kinetic process of the release of anticancer drugs and provide a powerful tool for the accurate treatment for cancers. This paper mainly introduces the research progress of prodrugs based on camptothecin, SN-38 and adriamycin, and the prospects for their development.

Key words: drug release, chemotherapy, cancer treatment, camptothecin, fluorescence small molecular

张继东,李家源,金华峰. 基于荧光效应的小分子抗癌药物释放体系研究进展[J]. 应用化学, 2019, 36(7): 733-748.

ZHANG Jidong,LI Jiayuan,JIN Huafeng. Research Progress on Small Molecule Anticancer Drug Release System Based on Fluorescence Effect[J]. Chinese Journal of Applied Chemistry, 2019, 36(7): 733-748.

参考文献

[1]	Chan J,Dodani S C,Chang C J.Reaction-Based Small-Molecule Fluorescent Probes for Chemoselective Bioimaging[J]. Nat Chem,2012,4(12):973-984.
[2]	Shcherbakova E G,Zhang B,Gozem S,et al. Supramolecular Sensors for Opiates and Their Metabolites[J]. J Am Chem Soc,2017,139(42):14954-14960.
[3]	You L,Zha D,Anslyn E V.Recent Advances in Supramolecular Analytical Chemistry Using Optical Sensing[J]. Chem Rev,2015,115(15):7840-7892.
[4]	Leng S,Qiao Q,Miao L,et al. A Wash-free SNAP-tag Fluorogenic Probe Based on the Additive Effects of Quencher Release and Environmental Sensitivity[J]. Chem Commun,2017,53(48):6448-6451.
[5]	Shao A,Xie Y,Zhu S,et al. Far-Red and Near-IR AIE-Active Fluorescent Organic Nanoprobes with Enhanced Tumor-Targeting Efficacy: Shape-Specific Effects[J]. Angew Chem Int Ed,2015,54(25):7275-7280.
[6]	Zhang J,She M,Li J,et al. Substituent Effect on Fluorescence Signaling of the Naphthalene Carbohydrazone Based Chemosensor:Its Implication in the Detection of Zn(II) Ions and Secondary Sensing PPi[J]. Sens Actuators B:Chem,2018,270:362-370.
[7]	Zhang J,Yan Z,Wang S,et al. Water Soluble Chemosensor for Ca2+ Based on Aggregation-Induced Emission Characteristics and Its Fluorescence Imaging in Living Cells[J]. Dyes Pigm,2018,150(0):112-120.
[8]	Wu L,Zou Y,Deng C,et al. Intracellular Release of Doxorubicin from Core-Crosslinked Polypeptide Micelles Triggered by both pH and Reduction Conditions[J]. Biomaterials,2013,34(21):5262-5272.
[9]	Yin C,Huo F,Zhang J,et al. Thiol-Addition Reactions and Their Applications in Thiol Recognition[J]. Chem Soc Rev,2013,42(14):6032-6059.
[10]	Minami T,Emami F,Nishiyabu R,et al. Quantitative Analysis of Modeled ATP Hydrolysis in Water by a Colorimetric Sensor Array[J]. Chem Commun,2016,52(50):7838-7841.
[11]	Gao M,Yu F,Lv C,et al. Fluorescent Chemical Probes for Accurate Tumor Diagnosis and Targeting Therapy[J]. Chem Soc Rev,2017,46(8):2237-2271.
[12]	Mei J,Huang Y,Tian H.Progress and Trends in AIE-Based Bioprobes:A Brief Overview[J]. ACS Appl Mater Interfaces,2018,10(15):12217-12261.
[13]	Li J,Chen L,Du L,et al. Cage the Firefly Luciferin!-A Strategy for Developing Bioluminescent Probes[J]. Chem Soc Rev,2013,42(2):662-676.
[14]	Qiu Y,Li X,Duan J Z.Influence of Drug Property and Product Design on in Vitro-in Vivo Correlation of Complex Modified-Release Dosage Forms[J]. J Pharm Sci,2014,103(2):507-516.
[15]	Malekzad H,Mirshekari H,Sahandi Zangabad P,et al. Plant Protein-Based Hydrophobic Fine and Ultrafine Carrier Particles in Drug Delivery Systems[J]. Crit Rev Biotechnol,2018,38(1):47-67.
[16]	Kakish H F,Tashtoush B,Ibrahim H G,et al. A Novel Approach for the Preparation of Highly Loaded Polymeric Controlled Release Dosage Forms of Diltiazem HCl and Diclofenac Sodium[J]. Eur J Pharm Biopharm,2002,54:75-81.
[17]	Kumar R,Shin W S,Sunwoo K,et al. Small Conjugate-Based Theranostic Agents:An Encouraging Approach for Cancer Therapy[J]. Chem Soc Rev,2015,44(19):6670-6683.
[18]	Wang Y,Zhang L,Zhang X,et al. Precise Polymerization of a Highly Tumor Microenvironment-Responsive Nanoplatform for Strongly Enhanced Intracellular Drug Release[J]. ACS Appl Mater Interfaces,2016,8(9):5833-5846.
[19]	Nasrolahi Shirazi A,Tiwari R,Chhikara B S,et al. Design and Biological Evaluation of Cell-Penetrating Peptide-Doxorubicin Conjugates as Prodrugs[J]. Mol Pharm,2013,10(2):488-499.
[20]	Rautio J,Kumpulainen H,Heimbach T,et al. Prodrugs:Design and Clinical Applications[J]. Nat Rev Drug Discov,2008,7(3):255-270.
[21]	Torchilin V.Tumor Delivery of Macromolecular Drugs Based on the EPR Effect[J]. Adv Drug Deliv Rev,2011,63(3):131-135.
[22]	Yuan Y,Kwok R T,Zhang R,et al. Targeted Theranostic Prodrugs Based on an Aggregation-Induced Emission(AIE) Luminogen for Real-time Dual-drug Tracking[J]. Chem Commun,2014,50(78):11465-11468.
[23]	Botella P,Muniesa C,Vicente V,et al. Effect of Drug Precursor in Cell Uptake and Cytotoxicity of Redox-Responsive Camptothecin Nanomedicines[J]. Mater Sci Eng C,2016,58:692-699.
[24]	Maiti S,Park N,Han J H,et al. Gemcitabine-Coumarin-Biotin Conjugates:A Target Specific Theranostic Anticancer Prodrug[J]. J Am Chem Soc,2013,135(11):4567-4572.
[25]	Wu X,Sun X,Guo Z,et al. In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug[J]. J Am Chem Soc,2014,136(9):3579-3588.
[26]	Ye M,Wang X,Tang J,et al. Dual-Channel NIR Activatable Theranostic Prodrug for in Vivo Spatiotemporal Tracking Thiol-Triggered Chemotherapy[J]. Chem Sci,2016,7(8):4958-4965.
[27]	Kong F,Liang Z,Luan D,et al. A Glutathione(GSH)-Responsive Near-Infrared(NIR) Theranostic Prodrug for Cancer Therapy and Imaging[J]. Anal Chem,2016,88(12):6450-6456.
[28]	Lee M H,Kim J Y,Han J H,et al. Direct Fluorescence Monitoring of the Delivery and Cellular Uptake of a Cancer-Targeted RGD Peptide-Appended Naphthalimide Theragnostic Prodrug[J]. J Am Chem Soc,2012,134(30):12668-12674.
[29]	Razgulin A,Ma N,Rao J.Strategies for in Vivo Imaging of Enzyme Activity:An Overview and Recent Advances[J]. Chem Soc Rev,2011,40(7):4186-4216.
[30]	Mendes A C,Zelikin A N.Enzyme Prodrug Therapy Engineered into Biomaterials[J]. Adv Funct Mater,2014,24(0):5202-5210.
[31]	Zhang J,Chai X,He X P,et al. Fluorogenic Probes for Disease-Relevant Enzymes[J]. Chem Soc Rev,2019,48(2):683-722.
[32]	Liu P,Xu J,Yan D,et al. A DT-Diaphorase Responsive Theranostic Prodrug for Diagnosis, Drug Release Monitoring and Therapy[J]. Chem Commun,2015,51(46):9567-9570.
[33]	Angenault S,Thirot S,Schmidt F,et al. Cancer Chemotherapy:A SN-38(7-Ethyl-10-hydroxycamptothecin) Glucuronide Prodrug for Treatment by a PMT(Prodrug monoTherapy) Strategy[J]. Bioorg Med Chem Lett,2003,13(5):947-950.
[34]	Kim E-J,Bhuniya S,Lee H,et al. An Activatable Prodrug for the Treatment of Metastatic Tumors[J]. J Am Chem Soc,2014,136(39):13888-13894.
[35]	Lesch H P,Kaikkonen M U,Pikkarainen J T,et al. Avidin-Biotin Technology in Targeted Therapy[J]. Expert Opin Drug Deliv,2010,7(5):551-564.
[36]	Bhuniya S,Maiti S,Kim E J,et al. An Activatable Theranostic for Targeted Cancer Therapy and Imaging[J]. Angew Chem,2014,126:4469-4475.
[37]	Dutta D,Alex S M,Bobba K N,et al. New Insight into a Cancer Theranostic Probe:Efficient Cell-Specific Delivery of SN-38 Guided by Biotinylated Poly(vinyl alcohol)[J]. ACS Appl Mater Interfaces,2016,8(0):33430-33438.
[38]	Zhou Y,Maiti M,Sharma A,et al. Azo-Based Small Molecular Hypoxia Responsive Rheranostic for Tumor-Specific Imaging and Therapy[J]. J Control Release,2018,288(0):14-22.
[39]	Whang C H,Yoo E,Hur S K,et al. A Highly GSH-Sensitive SN-38 Prodrug with an “OFF-to-ON” Fluorescence Switch as a Bifunctional Anticancer Agent[J]. Chem Commun,2018,54(65):9031-9034.
[40]	Akhter M Z,Sharma A,Rajeswari M R.Interaction of Adriamycin with a Promoter Region of Hmga1 and Its Inhibitory Effect on HMGA1 Expression in A431 Human Squamous Carcinoma Cell Line[J]. Mol Biosyst,2011,7(4):1336-1346.
[41]	Park S,Kim E,Kim W Y,et al. Biotin-Guided Anticancer Drug Delivery with Acidity-Triggered Drug Release[J]. Chem Commun,2015,51(45):9343-9345.
[42]	Kong X,Dong B,Song X,et al. Dual Turn-On Fluorescence Signal-Based Controlled Release System for Real-Time Monitoring of Drug Release Dynamics in Living Cells and Tumor Tissues[J]. Theranostics,2018,8(3):800-811.
[43]	Li S Y,Liu L H,Jia H Z,et al. A pH-Responsive Prodrug for Real-Time Drug Release Monitoring and Targeted Cancer Therapy[J]. Chem Commun,2014,50(80):11852-11855.
[44]	Xue X,Jin S,Zhang C,et al. Probe-Inspired Nano-Prodrug with Dual-color Fluorogenic Property Reveals Spatiotemporal Drug Release in Living Cells[J]. ACS Nano,2015,9:2729-2739.
[45]	Gao X,Cao J,Song Y,et al. A Unimolecular Theranostic System with H2O2-Specific Response and AIE-Activity for Doxorubicin Releasing and Real-Time Tracking in Living Cells[J]. RSC Adv,2018,8(20):10975-10979.
[46]	Bhuniya S,Lee M H,Jeon H M,et al. A Fluorescence Off-On Reporter for Real Time Monitoring of Gemcitabine Delivery to the Cancer Cells[J]. Chem Commun,2013,49:7141-7143.
[47]	Liu H W,Hu X X,Li K,et al. A Mitochondrial-Targeted Prodrug for NIR Imaging Guided and Synergetic NIR Photodynamic-Chemo Cancer Therapy[J]. Chem Sci,2017,8(11):7689-7695.
[48]	Liu Y,Zhu S,Gu K,et al. GSH-Activated NIR Fluorescent Prodrug for Podophyllotoxin Delivery[J]. ACS Appl Mater Interfaces,2017,9(35):29496-29504.
[49]	Cao Y,Pan R,Xuan W,et al. Photo-Triggered Fluorescent Theranostic Prodrugs as DNA Alkylating Agents for Mechlorethamine Release and Spatiotemporal Monitoring[J]. Org Biomol Chem,2015,13(24):6742-6748.